Immuneering (IMRX) vs Upstream Bio (UPB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Immuneering (IMRX) has outperformed Upstream Bio (UPB) over the past year, losing 36.8% versus a loss of 75.3%. Upstream Bio is the larger company by market cap ($252.5 million vs $249.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMRX | UPB |
|---|---|---|
| Share price | $3.86 | $4.61 |
| Market cap | $249.73M | $252.49M |
| 1-day change | +0.78% | +0.44% |
| YTD return | -41.34% | -83.02% |
| 1-year return | -36.82% | -75.31% |
| 5-year return | -84.47% | — |
| EPS (TTM) | $-0.93 | $-2.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.48 | $33.68 |
| 52-week low | $3.74 | $4.50 |
| Distance from 52-week high | -54.48% | -86.31% |
| Average volume | 693.70K | 605.35K |
| Shares outstanding | 64.70M | 54.77M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMRX has outperformed UPB by 38.5 percentage points over the past year.
IMRX vs UPB FAQ
Which is bigger, Immuneering or Upstream Bio?
Upstream Bio (UPB) is larger, with a market capitalization of $252.49M compared with $249.73M for Immuneering (IMRX).
Which stock has performed better over the past year, IMRX or UPB?
IMRX returned -36.82% over the past 12 months, compared with -75.31% for UPB (price return, excluding dividends). Past performance does not predict future results.
Are Immuneering and Upstream Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.